The small molecule inhibitor, bindarit, an indazolic derivative, which may down-regulate NF-κB through reduced phosphorylation of IκBα and p65 (Zollo et al., 2012), has subsequently been shown to modulate cancer cell proliferation and migration, impairing metastatic disease in murine models of prostate and breast cancer, through NF-κB and AKT inhibition (Zollo et al., 2012). This evidence concerns the gene NFKB1 and breast carcinoma.